Effectiveness of a Standardized Combination of Intracameral Mydriatics and Anaesthetic on Mydriasis during Cataract Surgery with Coexisting Diseases

Author:

Dereń-Szumełda Joanna Katarzyna1ORCID,Dorecka Mariola2,Zandecki Łukasz3,Mrukwa-Kominek Ewa45ORCID

Affiliation:

1. Military Institute of Aviation Medicine, Krasińskiego 54/56, 01-755 Warszawa, Poland

2. Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-514 Katowice, Poland

3. Collegium Medicum, Jan Kochanowski University of Kielce, Żeromskiego 5, 25-369 Kielce, Poland

4. Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland

5. Department of Ophthalmology, Kornel Gibiński University Clinical Center, Ceglana 35, 40-514 Katowice, Poland

Abstract

Purpose: To examine the effectiveness of a standardized combination of intracameral mydriatics and anesthetic (SCIMA) on mydriasis in patients with coexisting diseases such as diabetes mellitus (DM) and pseudoexfoliation syndrome (PXF) during phacoemulsification. Methods: Patients with cataract were included in the study if they achieved pupil dilation diameter ≥ 6.0 mm after the administration of mydriatic eyedrops (ME) during the first visit (V1). During the second visit (V2), pupil size measurements were obtained for phacoemulsification surgery with SCIMA. Effective mydriasis was defined as a pupil diameter ≥ 6.0 mm just prior to capsulorhexis without the use of additional pupil dilating agents. The measurements after ME administration during V1 and after SCIMA use during V2 were compared. Results: 103 patients (103 eyes) were divided into 3 groups: cataract and DM (n = 35), cataract and PXF (n = 32), and cataract without DM or PXF (n = 36). SCIMA administration allowed the achievement of effective mydriasis (≥6.0 mm) in all groups (n = 103; 100%). Mydriasis was significantly larger (p ≤ 0.001) after ME (7.3 mm) than after SCIMA (6.8 mm) administration. Conclusions: Patients with cataract and such comorbidities as DM or PXF are likely to achieve effective pharmacological mydriasis during cataract phacoemulsification after SCIMA application. Mydriasis after ME is slower and larger, while SCIMA is faster.

Publisher

MDPI AG

Subject

Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics

Reference52 articles.

1. Presbyopia and the aging eye: Existing refractive approaches and their potential impact on dry eye signs and symptoms;Lafosse;Contact Lens Anterior Eye,2019

2. Age-related cataract;Asbell;Lancet,2005

3. World Health Organization (2020). Priority Eye Diseases—Cataract, World Health Organization. Available online: https://www.who.int/blindness/causes/priority/en/index1.html.

4. American Academy of Ophthalmology (2016). 2016–2017 Basic and Clinical Science Course: Section 11: Lens and Cataract, American Academy of Ophthalmology. [2016th ed.].

5. Narodowy Fundusz Zdrowia (2023, October 20). Statystyka NFZ—Statystyki Świadczenia, Available online: https://statystyki.nfz.gov.pl/Benefits/1a?S.Section=B+-+Choroby+oczu&S.Name=B19+USUNI%C4%98CIE+ZA%C4%86MY+NIEPOWIK%C5%81ANEJ+Z+JEDNOCZESNYM+WSZCZEPIENIEM+SOCZEWKI&S.Catalog=1a&S.Year=0&S.SelectedTab=BasicData&search=true.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3